Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham cover art

Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham

Melinda Knows Best: EADV 2025 Chronic Hand Eczema Paris Pop-Up with Dr.Melinda Gooderham

Listen for free

View show details

About this listen

 Paris Pop-Up: Hands Down the Most Fun You’ll Have Learning About Chronic Hand Eczema Late Breaker EditionChronic Hand Eczema in Focus: DELTA-Teen efficacy & pooled safety of topical pan-JAK Episode Tasting Menu 🍽️:Jet-lag ✈️, steak-frites , and NEW science : we unpack fresh adolescent data for a topical pan-JAK cream in chronic hand eczema (CHE) and a pooled safety package that’s so uneventful it’s…beautiful 😌. (Melinda’s words: “Boring is good.”)Fresh from EADV Paris 🗼🇫🇷, the team breaks down two late-breaking updates on CHE:DELTA-Teen — a randomized (3:1) 16-week trial of a topical pan-JAK inhibitor (delgocitinib cream) in adolescents (12–17) with moderate–severe CHE. 📊Pooled safety analysis across five trials (Phase 2b/3; 16-week regular use + up to 52-week as-needed). 🛡️📈What’s on the tasting menu :• EADV in Paris — highlights with a dash of Melinda’s Paris story 🥐📸• Current adolescent CHE care — steroid limits & non-steroidal gaps • DELTA-Teen unpacked — design, endpoints, results, onset, adherence impact • Safety deep-dive — pooled 5-trial analysis, 52-week PRN, counseling talking points • Practice pearls — payer metrics (IGA-CHE), cross-setting messaging, fast-tracking from primary care • Wrap — off-label nuance, what to tell parents/teens, what to watch for nextWe dive into where a non-steroidal topical JAK can fit for adolescents—an area with gaps given steroid hesitancy and tolerability issues with other non-steroidals 🧩.Plus, a practical workflow map 🗺️: primary care triage → dermatology fast-track → pharmacy counseling (steroid fears, adherence benefits from rapid itch relief) → documentation (expect IGA-CHE to be required by payers). Importantly, efficacy signals span CHE subtypes (atopic, irritant, allergic) ✅—supporting broad real-world relevance 🌍. Learning objectives 🎯:Describe the DELTA-Teen trial design for adolescent CHE, including primary (IGA-CHE TS) and key secondary endpoints (HECSI-90, HESD itch/pain).Interpret week-16 efficacy results and differentiate early patient-reported benefits from statistical-significance timing (e.g., week-12 separation)—and weave this into adherence counseling ⏳.Summarize pooled safety across five trials (16-week regular use + up to 52-week PRN): common AEs, no increased AE rates vs vehicle, and implications of minimal systemic absorption & no boxed warning for topical delgocitinib 🛡️📉.Identify gaps in adolescent CHE management (steroid limitations, tolerability of other non-steroidals) and position topical pan-JAK inhibitors appropriately—acknowledging off-label use where applicable 🧭.Apply a care-pathway playbook (primary care → dermatology → pharmacy counseling → payer documentation) and document outcomes likely required for access (e.g., IGA-CHE scoring) across CHE subtypes 📋✅. Practical pearls (AKA Clinic Cheat Codes) :• Expect early itch relief that can boost adherence; set expectations about week-12 statistical separation ⏱️🙌.• Use IGA-CHE in documentation; keep HECSI-90/HESD in mind for research/quality initiatives 📝🔍.• Safety talking points: AEs comparable to vehicle; long-term PRN data up to 52 weeks; discuss the no boxed warning context vs class concerns 🛡️🗣️.• Reinforce steroid-sparing options to address teen/parent anxieties about skin thinning 🧴.• Subtype-agnostic efficacy supports practical use while you sort mixed etiologies 🧪🔄.—Notes ⚠️🗒️: Adolescent use discussed here reflects off-label prescribing in many regions pending any label extension. Always consult local product labeling and guidance.#SkinAndJointsPodcast #ChronicHandEczema #CHE #EADV2025 #Paris #Dermatology #DELTATeen #Delgocitinib #JAKInhibitor #TopicalJAK #AdolescentDerm #PediatricDerm #ItchRelief #SteroidSparing #ClinicalTrials #RealWorldEvidence #IGACHE #HECSI90 #HESD #PracticePearls #DermPharmacy #MedEd #HCPs #EvidenceBasedDermSUPPORTED BY AN IME GRANT FROM LEO PHARMA ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)Toronto, ONMelinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.📻www.skinandjoints.ca✉️info@skinandjoints.ca 📻www.skinandjoints.ca✉️info@skinandjoints.ca Hosted ...
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.